March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...

AstraZeneca stock jumped Friday after the U.K.-based drugmaker said its COPD drug succeeded in two final-phase studies.

GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33, an alarmin cytokine.

Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

The Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) and Informing the Pathway of Chronic ...

COPD is a progressive respiratory condition characterised by airway obstruction, reduced lung function, and episodic symptom flare-ups. The disease affects an estimated 1.2 million people with a ...

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Use of CT is proven to save lives in patients eligible for lung cancer screening, which includes most patients with COPD, said Barr, professor of medicine and epidemiology at Columbia University ...

You did it to yourself.” This is one of the things that patients who are diagnosed with COPD often hear because of the stigma ...